# The PANoptotic mosaic of rheumatoid arthritis: epitranscriptomic regulation, systemic relays, and precision death-mode editing

## TL;DR

This study explores how a new programmed cell death system, called PANoptosis, drives rheumatoid arthritis and suggests new precision treatments beyond traditional immunosuppression.

## Contribution

The paper introduces the PANoptosis framework, linking multiple cell death modes and systemic signals in rheumatoid arthritis pathogenesis.

## Key findings

- PANoptosis integrates apoptosis, pyroptosis, and necroptosis in synovial cell death disruption.
- Environmental stressors and epitranscriptomic changes drive PANoptosome assembly and inflammation.
- Bio-responsive nanoplatforms can reprogram cell death modes to resolve inflammation.

## Abstract

The persistence of difficult-to-treat rheumatoid arthritis (D2T-RA) underscores a fundamental disruption in synovial cell death homeostasis, transcending the limitations of conventional cytokine blockade. By integrating multi-omics, molecular imaging, and bio-responsive nanotechnologies, we characterized the PANoptosis framework—a synergistic programmed cell death (PCD) system converging apoptosis, pyroptosis, and necroptosis. Our findings reveal that environmental stressors perturb cellular antioxidant defenses, thereby precipitating PANoptosome assembly through mechanisms such as autoantibody-mediated biophysical triggers. Systemic crosstalk, spanning lung-derived inflammatory signals and gut metabolic rheostats, orchestrates synovial fate. Mechanistically, epitranscriptomic RNA methylation and dysregulated molecular switches within the PANoptosome drive inflammatory flares, while distal effects involve extracellular vesicle-mediated cartilage damage. Therapeutic interventions, such as bio-responsive nanoplatforms, effectively reprogram death modes toward inflammatory resolution. We conclude that PANoptosis is a central driver of RA pathogenesis, and its precision targeting via “death-mode editing” represents a paradigm shift from broad immunosuppression toward curative interventions. This work establishes a comprehensive PANoptic model and identifies actionable therapeutic avenues, offering transformative potential for the clinical management of RA.